Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
19 Maio 2023 - 5:01PM
Journey Medical Corporation (“Journey Medical” or the “Company”)
(Nasdaq: DERM), a commercial-stage pharmaceutical company that
focuses on the development and commercialization of pharmaceutical
products for the treatment of dermatological conditions, today
announced the Company will release its first quarter 2023 financial
results after the U.S. financial markets close on Monday, May 22,
2023. Journey Medical management will conduct a conference call and
audio webcast on Monday, May 22, 2023 at 4:30 p.m. ET.
To listen to the conference call, interested
parties within the U.S. should dial 1-866-777-2509 (domestic) or
1-412-317-5413 (international). All callers should dial in
approximately 10 minutes prior to the scheduled start time and ask
to join the Journey Medical conference call. Participants can
register for the conference by navigating
to https://dpregister.com/sreg/10178597/f951c8551f.
Please note that registered participants will receive their
dial-in number upon registration.
A live audio webcast can be accessed on the News
and Events page of the Investors section of Journey Medical’s
website, www.journeymedicalcorp.com, and will remain available for
replay for approximately 30 days after the conference call.
About Journey Medical
CorporationJourney Medical Corporation (Nasdaq: DERM)
(“Journey Medical”) is focused on identifying, acquiring,
developing and strategically commercializing innovative,
differentiated dermatology products through its efficient sales and
marketing model. The company currently markets eight products that
help treat and heal common skin conditions. The Journey Medical
team comprises industry experts with extensive experience in
developing and commercializing some of dermatology’s most
successful prescription brands. Journey Medical is located in
Scottsdale, Arizona and was founded by Fortress Biotech, Inc.
(Nasdaq: FBIO). Journey Medical’s common stock is registered under
the Securities Exchange Act of 1934, as amended, and it files
periodic reports with the U.S. Securities and Exchange Commission
(“SEC”). For additional information about Journey Medical, visit
www.journeymedicalcorp.com.
Company Contact:Jaclyn Jaffe
Journey Medical Corporation(781) 652-4500ir@jmcderm.com
Media Relations Contact:Tony
Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com
Journey Medical (NASDAQ:DERM)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Journey Medical (NASDAQ:DERM)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024